Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-04-27

AUTHORS

Mark Evans, Zoë Welsh, Alexander Seibold

ABSTRACT

IntroductionReal-world evidence (RWE) confirms that reductions in HbA1c for children and adults with type 1 diabetes (T1DM) and adults with type 2 diabetes (T2DM) are associated with use of the FreeStyle Libre system. This current meta-analysis aims to investigate whether HbA1c benefits are sustained over 24 months and to identify patterns of change in HbA1c for users of the FreeStyle Libre system for people living with T1DM or T2DM.MethodsA bibliographic search up to December 2020 identified 75 studies reporting data on change in lab HbA1c in 30,478 participants with type 1 (n = 28,063; 62 trials) or type 2 diabetes (n = 2415; 13 trials) using the FreeStyle Libre system, including observations on children, adolescents and adults. Meta-analysis was performed using a random effects model.ResultsReductions in HbA1c at 3–4 months were similar for adults with T1DM (− 0.53%, 95% CI − 0.69 to − 0.38) or with T2DM (− 0.45%, 95% CI − 0.57 to − 0.33), continuing through 4.5–7.5 months in T1DM (− 0.42%, 95% CI − 0.58 to − 0.27) and in T2DM (− 0.59%, 95% CI − 0.80 to − 0.39). Meta-regression analysis shows that higher starting HbA1c is correlated with greater reductions in HbA1c in T1DM and in T2DM. These patterns of change in HbA1c were sustained for 24 months in T1DM and for at least 12 months in T2DM.ConclusionsMeta-analysis of RWE confirms that using the FreeStyle Libre system is associated with significant reductions in HbA1c for adults with T1DM or with T2DM. Reductions are greater for people with higher baseline HbA1c and are sustained for 24 and 12 months in T1DM and TD2M respectively. More... »

PAGES

1175-1185

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-022-01253-9

DOI

http://dx.doi.org/10.1007/s13300-022-01253-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147398390

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35476279


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wellcome Trust/MRC Institute of Metabolic Science, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Hills Road, IMS MRL Box 289, CB2 0QQ, Cambridge, UK", 
          "id": "http://www.grid.ac/institutes/grid.120073.7", 
          "name": [
            "Wellcome Trust/MRC Institute of Metabolic Science, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Hills Road, IMS MRL Box 289, CB2 0QQ, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Evans", 
        "givenName": "Mark", 
        "id": "sg:person.0752030520.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752030520.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abbott Diabetes Care, Range Road, Witney, OX28 3FP, Oxfordshire, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Abbott Diabetes Care, Range Road, Witney, OX28 3FP, Oxfordshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Welsh", 
        "givenName": "Zo\u00eb", 
        "id": "sg:person.011536100730.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011536100730.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abbott Diabetes Care, Max-Planck-Ring 2, 65205, Wiesbaden, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Abbott Diabetes Care, Max-Planck-Ring 2, 65205, Wiesbaden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seibold", 
        "givenName": "Alexander", 
        "id": "sg:person.015373573342.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015373573342.27"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.3758/bf03195354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025666111", 
          "https://doi.org/10.3758/bf03195354"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-020-00978-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1133442360", 
          "https://doi.org/10.1007/s13300-020-00978-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-016-0223-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024814077", 
          "https://doi.org/10.1007/s13300-016-0223-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-00720-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122231011", 
          "https://doi.org/10.1007/s13300-019-00720-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-014-3272-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037177899", 
          "https://doi.org/10.1007/s00125-014-3272-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-04-27", 
    "datePublishedReg": "2022-04-27", 
    "description": "IntroductionReal-world evidence (RWE) confirms that reductions in HbA1c for children and adults with type\u00a01 diabetes (T1DM) and adults with type\u00a02 diabetes (T2DM) are associated with use of the FreeStyle Libre system. This current meta-analysis aims to investigate whether HbA1c benefits are sustained over 24\u00a0months and to identify patterns of change in HbA1c for users of the FreeStyle Libre system for people living with T1DM or T2DM.MethodsA bibliographic search up to December 2020 identified 75 studies reporting data on change in lab HbA1c in 30,478 participants with type\u00a01 (n\u2009=\u200928,063; 62 trials) or type\u00a02 diabetes (n\u2009=\u20092415; 13 trials) using the FreeStyle Libre system, including observations on children, adolescents and adults. Meta-analysis was performed using a random effects model.ResultsReductions in HbA1c at 3\u20134\u00a0months were similar for adults with T1DM (\u2212\u00a00.53%, 95%\u00a0CI \u2212\u00a00.69 to \u2212\u00a00.38) or with T2DM (\u2212\u00a00.45%, 95%\u00a0CI \u2212\u00a00.57 to \u2212\u00a00.33), continuing through 4.5\u20137.5\u00a0months in T1DM (\u2212\u00a00.42%, 95%\u00a0CI \u2212\u00a00.58 to \u2212\u00a00.27) and in T2DM (\u2212\u00a00.59%, 95%\u00a0CI \u2212\u00a00.80 to \u2212\u00a00.39). Meta-regression analysis shows that higher starting HbA1c is correlated with greater reductions in HbA1c in T1DM and in T2DM. These patterns of change in HbA1c were sustained for 24\u00a0months in T1DM and for at least 12\u00a0months in T2DM.ConclusionsMeta-analysis of RWE confirms that using the FreeStyle Libre system is associated with significant reductions in HbA1c for adults with T1DM or with T2DM. Reductions are greater for people with higher baseline HbA1c and are sustained for 24 and 12\u00a0months in T1DM and TD2M respectively.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01253-9", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "FreeStyle Libre system", 
      "Meta-Analysis", 
      "real-world observational study", 
      "higher baseline HbA1c", 
      "MethodsA bibliographic search", 
      "flash glucose monitoring", 
      "random-effects model", 
      "meta-regression analysis", 
      "patterns of change", 
      "TD2M", 
      "baseline HbA1c", 
      "observational study", 
      "HbA1c", 
      "T2DM", 
      "T1DM", 
      "diabetes", 
      "glucose monitoring", 
      "months", 
      "adults", 
      "bibliographic search", 
      "greater reduction", 
      "significant reduction", 
      "effects model", 
      "children", 
      "ResultsReduction", 
      "reduction", 
      "adolescents", 
      "study", 
      "changes", 
      "participants", 
      "people", 
      "evidence", 
      "patterns", 
      "types", 
      "benefits", 
      "RWE", 
      "search", 
      "monitoring", 
      "use", 
      "data", 
      "analysis", 
      "system", 
      "observations", 
      "model", 
      "users"
    ], 
    "name": "Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies", 
    "pagination": "1175-1185", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147398390"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01253-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35476279"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01253-9", 
      "https://app.dimensions.ai/details/publication/pub.1147398390"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_939.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01253-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01253-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01253-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01253-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01253-9'


 

This table displays all metadata directly associated to this object as RDF triples.

145 TRIPLES      21 PREDICATES      75 URIs      62 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-022-01253-9 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N24abc2c19da248d190959fc40269bd9f
4 schema:citation sg:pub.10.1007/s00125-014-3272-2
5 sg:pub.10.1007/s13300-016-0223-6
6 sg:pub.10.1007/s13300-019-00720-0
7 sg:pub.10.1007/s13300-020-00978-9
8 sg:pub.10.3758/bf03195354
9 schema:datePublished 2022-04-27
10 schema:datePublishedReg 2022-04-27
11 schema:description IntroductionReal-world evidence (RWE) confirms that reductions in HbA1c for children and adults with type 1 diabetes (T1DM) and adults with type 2 diabetes (T2DM) are associated with use of the FreeStyle Libre system. This current meta-analysis aims to investigate whether HbA1c benefits are sustained over 24 months and to identify patterns of change in HbA1c for users of the FreeStyle Libre system for people living with T1DM or T2DM.MethodsA bibliographic search up to December 2020 identified 75 studies reporting data on change in lab HbA1c in 30,478 participants with type 1 (n = 28,063; 62 trials) or type 2 diabetes (n = 2415; 13 trials) using the FreeStyle Libre system, including observations on children, adolescents and adults. Meta-analysis was performed using a random effects model.ResultsReductions in HbA1c at 3–4 months were similar for adults with T1DM (− 0.53%, 95% CI − 0.69 to − 0.38) or with T2DM (− 0.45%, 95% CI − 0.57 to − 0.33), continuing through 4.5–7.5 months in T1DM (− 0.42%, 95% CI − 0.58 to − 0.27) and in T2DM (− 0.59%, 95% CI − 0.80 to − 0.39). Meta-regression analysis shows that higher starting HbA1c is correlated with greater reductions in HbA1c in T1DM and in T2DM. These patterns of change in HbA1c were sustained for 24 months in T1DM and for at least 12 months in T2DM.ConclusionsMeta-analysis of RWE confirms that using the FreeStyle Libre system is associated with significant reductions in HbA1c for adults with T1DM or with T2DM. Reductions are greater for people with higher baseline HbA1c and are sustained for 24 and 12 months in T1DM and TD2M respectively.
12 schema:genre article
13 schema:isAccessibleForFree true
14 schema:isPartOf N16eb17ee998b41baa51d731f4b1671f2
15 Naa33d8caf7ec4d809883d70772c2b129
16 sg:journal.1044057
17 schema:keywords FreeStyle Libre system
18 HbA1c
19 Meta-Analysis
20 MethodsA bibliographic search
21 RWE
22 ResultsReduction
23 T1DM
24 T2DM
25 TD2M
26 adolescents
27 adults
28 analysis
29 baseline HbA1c
30 benefits
31 bibliographic search
32 changes
33 children
34 data
35 diabetes
36 effects model
37 evidence
38 flash glucose monitoring
39 glucose monitoring
40 greater reduction
41 higher baseline HbA1c
42 meta-regression analysis
43 model
44 monitoring
45 months
46 observational study
47 observations
48 participants
49 patterns
50 patterns of change
51 people
52 random-effects model
53 real-world observational study
54 reduction
55 search
56 significant reduction
57 study
58 system
59 types
60 use
61 users
62 schema:name Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies
63 schema:pagination 1175-1185
64 schema:productId N2daee002723d4f3cad941da6df5f9c9f
65 N44f142c75dc3458b80bd470f5a55523d
66 N452696ff03054159b4472318f99ab16e
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147398390
68 https://doi.org/10.1007/s13300-022-01253-9
69 schema:sdDatePublished 2022-08-04T17:13
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher N1031955f1d7148ab8cefb4823ca35f47
72 schema:url https://doi.org/10.1007/s13300-022-01253-9
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N1031955f1d7148ab8cefb4823ca35f47 schema:name Springer Nature - SN SciGraph project
77 rdf:type schema:Organization
78 N16eb17ee998b41baa51d731f4b1671f2 schema:volumeNumber 13
79 rdf:type schema:PublicationVolume
80 N24abc2c19da248d190959fc40269bd9f rdf:first sg:person.0752030520.95
81 rdf:rest N4a1aafbc9bec4c789e3911deb2c0d2f9
82 N2daee002723d4f3cad941da6df5f9c9f schema:name doi
83 schema:value 10.1007/s13300-022-01253-9
84 rdf:type schema:PropertyValue
85 N44f142c75dc3458b80bd470f5a55523d schema:name pubmed_id
86 schema:value 35476279
87 rdf:type schema:PropertyValue
88 N452696ff03054159b4472318f99ab16e schema:name dimensions_id
89 schema:value pub.1147398390
90 rdf:type schema:PropertyValue
91 N4a1aafbc9bec4c789e3911deb2c0d2f9 rdf:first sg:person.011536100730.18
92 rdf:rest Na425d52ad49c45028fc9baf44395d640
93 Na425d52ad49c45028fc9baf44395d640 rdf:first sg:person.015373573342.27
94 rdf:rest rdf:nil
95 Naa33d8caf7ec4d809883d70772c2b129 schema:issueNumber 6
96 rdf:type schema:PublicationIssue
97 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
98 schema:name Medical and Health Sciences
99 rdf:type schema:DefinedTerm
100 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
101 schema:name Clinical Sciences
102 rdf:type schema:DefinedTerm
103 sg:journal.1044057 schema:issn 1869-6953
104 1869-6961
105 schema:name Diabetes Therapy
106 schema:publisher Springer Nature
107 rdf:type schema:Periodical
108 sg:person.011536100730.18 schema:affiliation grid-institutes:None
109 schema:familyName Welsh
110 schema:givenName Zoë
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011536100730.18
112 rdf:type schema:Person
113 sg:person.015373573342.27 schema:affiliation grid-institutes:None
114 schema:familyName Seibold
115 schema:givenName Alexander
116 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015373573342.27
117 rdf:type schema:Person
118 sg:person.0752030520.95 schema:affiliation grid-institutes:grid.120073.7
119 schema:familyName Evans
120 schema:givenName Mark
121 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752030520.95
122 rdf:type schema:Person
123 sg:pub.10.1007/s00125-014-3272-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037177899
124 https://doi.org/10.1007/s00125-014-3272-2
125 rdf:type schema:CreativeWork
126 sg:pub.10.1007/s13300-016-0223-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024814077
127 https://doi.org/10.1007/s13300-016-0223-6
128 rdf:type schema:CreativeWork
129 sg:pub.10.1007/s13300-019-00720-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122231011
130 https://doi.org/10.1007/s13300-019-00720-0
131 rdf:type schema:CreativeWork
132 sg:pub.10.1007/s13300-020-00978-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1133442360
133 https://doi.org/10.1007/s13300-020-00978-9
134 rdf:type schema:CreativeWork
135 sg:pub.10.3758/bf03195354 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025666111
136 https://doi.org/10.3758/bf03195354
137 rdf:type schema:CreativeWork
138 grid-institutes:None schema:alternateName Abbott Diabetes Care, Max-Planck-Ring 2, 65205, Wiesbaden, Germany
139 Abbott Diabetes Care, Range Road, Witney, OX28 3FP, Oxfordshire, UK
140 schema:name Abbott Diabetes Care, Max-Planck-Ring 2, 65205, Wiesbaden, Germany
141 Abbott Diabetes Care, Range Road, Witney, OX28 3FP, Oxfordshire, UK
142 rdf:type schema:Organization
143 grid-institutes:grid.120073.7 schema:alternateName Wellcome Trust/MRC Institute of Metabolic Science, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Hills Road, IMS MRL Box 289, CB2 0QQ, Cambridge, UK
144 schema:name Wellcome Trust/MRC Institute of Metabolic Science, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Hills Road, IMS MRL Box 289, CB2 0QQ, Cambridge, UK
145 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...